» Articles » PMID: 18563734

The Influence of Conservative Surgical Practices for Malignant Ovarian Germ Cell Tumors

Overview
Journal J Surg Oncol
Date 2008 Jun 20
PMID 18563734
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate demographics, survival, and surgical trends for patients with malignant ovarian germ cell tumors.

Methods: SEER data abstracted from 1988 to 2001 and analyzed using Kaplan-Meier and Cox regression models.

Results: Of 760 patients, the median age was 23 years. Seventy-six percent of patients presented with stage I-II disease, and 24% with stage III-IV. Fifty-five percent were immature teratomas, 32% dysgerminomas, and 13% yolk sac tumors. Fertility-preserving surgery was performed in 41.2% (n = 313) of patients. In those <45 years old, the use of fertility-preserving surgery increased from 40.5% to 44.5% to 48.4% over the time periods 1988-1992, 1993-1997, 1998-2001 (P = 0.25). The survival of patients who underwent fertility-preserving surgery was not statistically different compared to those who underwent standard surgery (P = 0.26). Patients with stage I-II disease had improved survival compared to stage III-IV disease (97.6% vs. 85.5%, P < 0.001). The overall survival of women with dysgerminomas, immature teratomas, and yolk sac tumors was 99.5%, 94.3%, and 85.4%, respectively (P < 0.001). In multivariate analysis, older age, advanced stage, and yolk sac tumor histology predicted for poorer survival.

Conclusion: Our data suggests that the use of fertility-preserving surgery with concomitant surgical staging for germ cell cancers has increased without compromising survival.

Citing Articles

Yolk sac ovarian cancer with mesenteric metastases.

Irawan B, Tjokroprawiro B BMJ Case Rep. 2025; 18(2).

PMID: 39933864 PMC: 11814948. DOI: 10.1136/bcr-2024-261399.


Yolk Sac Tumor of the Ovary in Mosaic 46XX Turner Syndrome.

Suryawan A, Tjahyadi D, Hermawan M, Aprialdi D Int J Womens Health. 2024; 16:629-635.

PMID: 38645982 PMC: 11032139. DOI: 10.2147/IJWH.S462375.


Obstetric Results after Fertility-Sparing Management of Non-Epithelial Ovarian Cancer.

Piatek S, Szymusik I, Sobiczewski P, Michalski W, Kowalska M, Oltarzewski M Cancers (Basel). 2023; 15(16).

PMID: 37627198 PMC: 10453521. DOI: 10.3390/cancers15164170.


Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.

Chu R, Liu P, Chen J, Cheng X, Li K, Che Y J Gynecol Oncol. 2023; 34(2):e12.

PMID: 36890292 PMC: 9995871. DOI: 10.3802/jgo.2023.34.e12.


Paediatric Ovarian Dysgerminoma: A Case Report.

Adhikari S, Joti S, Chhetri P JNMA J Nepal Med Assoc. 2023; 60(255):985-988.

PMID: 36705173 PMC: 9795100. DOI: 10.31729/jnma.7894.


References
1.
Hankey B, Ries L, Edwards B . The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8(12):1117-21. View

2.
Tewari K, Di Saia P . Ovulatory failure, fertility preservation and reproductive strategies in the setting of gynecologic and non-gynecologic malignancies. Eur J Gynaecol Oncol. 2006; 27(5):449-61. View

3.
Williams S, Kauderer J, Burnett A, Lentz S, Aghajanian C, Armstrong D . Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004; 95(3):496-9. DOI: 10.1016/j.ygyno.2004.07.044. View

4.
Tyler Jr C, Lee N, Robboy S, Kurman R, Paris A, Wingo P . The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?. Am J Obstet Gynecol. 1991; 164(1 Pt 1):65-70. DOI: 10.1016/0002-9378(91)90628-5. View

5.
Brewer M, Gershenson D, Herzog C, Mitchell M, Silva E, Wharton J . Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999; 17(9):2670-75. DOI: 10.1200/JCO.1999.17.9.2670. View